Public Release: 

Enterotrack commercializing device for non-invasive inflammation monitoring

Non-invasive device enables better monitoring of esophageal disease and inflammation

University of Colorado Anschutz Medical Campus

AURORA, Colo. (Jan. 6, 2015) - EnteroTrack, LLC and the University of Colorado (CU) have executed an exclusive license agreement that will allow the company to develop and market a novel device to monitor inflammation of the gastrointestinal tract.

Diagnosing inflammatory conditions of the gastrointestinal tract such as eosinophilic esophagitis (EoE), severe gastroesophageal reflux (GERD), eosinophilic gastroenteritis (EGE), food allergic enteropathy (FAE), and inflammatory bowel disease (lBD) is often difficult, since blood tests and radio-imaging aren't able to pinpoint the cause of inflammation. Ultimately, many patients must undergo endoscopy - use of an instrument to visualize the esophagus and collect samples for testing.

EnteroTrack LLC is developing a capsule that allows for simple, low-cost analysis of esophageal content. The capsule can help identify the presence of esophageal inflammation, leading to faster treatment. The capsule can also be used to monitor the effectiveness of treatment, and in the future may also be used to help diagnose esophageal diseases.

The company was formed as a result of a partnership between Glenn T. Furuta, M.D., a professor of pediatrics at the CU School of Medicine at the Anschutz Medical Campus and a pediatric gastroenterologist at Children's Hospital Colorado; Robin Shandas, Ph.D., professor and chair of bioengineering at the University of Colorado Denver, College of Engineering and Applied Science; and Steven Ackerman, Ph.D., a professor of biochemistry at the University of Illinois College of Medicine at Chicago.

"This partnership represents the best aspect of academic medicine," said Furuta. "We have been able to successfully collaborate in a multi-disciplinary fashion to develop and execute a plan that will ultimately improve the lives children and adults with gastrointestinal diseases."

Furuta developed the technology in collaboration with Ackerman; the duo then approached Shandas to move the idea from the university research lab into a commercial entity.

At that time, Children's Hospital Colorado stepped in to provide seed funding to the company, supporting the innovative research of the researchers and recognizing the opportunity to positively impact the lives of children with inflammatory conditions of the gastrointestinal track.

"Given the increasing pressures to contain costs, there is clear rationale for innovative, cost-effective methods to monitor esophageal diseases," said Shandas, who is acting as the company's interim CEO. "This technology holds particular promise because it can reduce total patient care costs while keeping good margins. We hope to obtain FDA approval for the device in 2015."

###

About EnteroTrack

EnteroTrack aims to be a key player in the field of detecting gastrointestinal (GI) biomarkers to monitor various diseases in children and adults. In contrast to current, more invasive approaches or less direct methods, the company's products are minimally invasive and targeted for specific organs and diseases. The diagnostic market for GI diseases in the US exceeds $1B annually. The company has received funding from Children's Hospital Colorado, and from the State of Colorado's Bioscience Discovery and Evaluation Grant program.

About the Technology Transfer Office and the University of Colorado:

The CU Technology Transfer Office pursues, protects, packages, and licenses to business the intellectual property generated from research at CU. Tech Transfer provides assistance to faculty, staff, and students, as well as to businesses looking to license or invest in CU technology. For more information about technology transfer at CU, visit http://www.cu.edu/techtransfer.

The University of Colorado is a premier public research university with four campuses: the University of Colorado Boulder, the University of Colorado Colorado Springs, the University of Colorado Denver and the University of Colorado Anschutz Medical Campus. With nearly 59,700 students, over 4,900 full-time instructional faculty members and an additional 1,200 research faculty members across the four campuses, CU is the largest institution of higher education in the state of Colorado. CU researchers attracted more than $861M in sponsored research funding in fiscal year 2013-14. Academic prestige is marked by the university's five Nobel laureates, eight MacArthur "genius" Fellows, 18 alumni astronauts and 19 Rhodes Scholars. For more information about the entire CU system, and to access campus resources, go to http://www.cu.edu.

About the Technology Transfer Office and the University of Illinois at Chicago

The University of Illinois at Chicago, home to the nation's largest college of medicine, is a leader in moving path-breaking research into innovative, real-world applications. The UIC Office of Technology Management encourages innovation and facilitates economic development through the effective management, transfer, and commercialization of UIC technologies and intellectual property.

Contact: lindsay.lennox@cu.edu or robin shandas at enterotrackr@gmail.com

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.